$UTMD
UTAH MEDICAL PRODUCTS INC

2023 Q2 Form 10-Q Financial Statement

#000181188423000013 Filed on May 05, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $12.87M $12.52M $12.32M
YoY Change -4.19% 1.6% 12.44%
Cost Of Revenue $5.127M $4.677M $4.790M
YoY Change -2.84% -2.36% 19.15%
Gross Profit $7.739M $7.843M $7.533M
YoY Change -5.05% 4.12% 8.39%
Gross Profit Margin 60.15% 62.64% 61.13%
Selling, General & Admin $3.181M $3.260M $2.888M
YoY Change 7.5% 12.88% -1.43%
% of Gross Profit 41.1% 41.57% 38.34%
Research & Development $133.0K $144.0K $123.0K
YoY Change -1.48% 17.07% -5.38%
% of Gross Profit 1.72% 1.84% 1.63%
Depreciation & Amortization $1.766M $155.0K $1.795M
YoY Change 0.11% -91.36% -1.37%
% of Gross Profit 22.82% 1.98% 23.83%
Operating Expenses $3.314M $3.404M $3.011M
YoY Change 7.11% 13.05% -1.6%
Operating Profit $4.425M $4.439M $4.522M
YoY Change -12.5% -1.84% 16.25%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $747.0K $680.0K $8.000K
YoY Change 426.06% 8400.0% -20.0%
Pretax Income $5.172M $5.119M $4.530M
YoY Change -0.52% 13.0% 16.15%
Income Tax $972.0K $905.0K $996.0K
% Of Pretax Income 18.79% 17.68% 21.99%
Net Earnings $4.200M $4.214M $3.534M
YoY Change 2.36% 19.24% 16.87%
Net Earnings / Revenue 32.64% 33.66% 28.68%
Basic Earnings Per Share $1.16 $1.16 $0.97
Diluted Earnings Per Share $1.15 $1.16 $964.3K
COMMON SHARES
Basic Shares Outstanding 3.628M shares 3.628M shares 3.655M shares
Diluted Shares Outstanding 3.639M shares 3.636M shares 3.665M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.62M $80.91M $65.87M
YoY Change 27.78% 22.83% 17.63%
Cash & Equivalents $84.62M $80.91M $65.87M
Short-Term Investments
Other Short-Term Assets $467.0K $442.0K $520.0K
YoY Change 3.09% -15.0% 4.0%
Inventory $10.12M $9.940M $7.367M
Prepaid Expenses
Receivables $3.604M $3.818M $5.720M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $98.81M $95.11M $79.48M
YoY Change 25.15% 19.67% 19.34%
LONG-TERM ASSETS
Property, Plant & Equipment $10.54M $10.24M $11.00M
YoY Change 3.64% -6.87% -0.93%
Goodwill $13.68M $13.50M
YoY Change 2.09%
Intangibles $7.451M $8.915M
YoY Change -43.59%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $31.67M $32.66M $40.32M
YoY Change -14.86% -19.01% -15.64%
TOTAL ASSETS
Total Short-Term Assets $98.81M $95.11M $79.48M
Total Long-Term Assets $31.67M $32.66M $40.32M
Total Assets $130.5M $127.8M $119.8M
YoY Change 12.33% 6.65% 4.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.336M $1.028M $1.454M
YoY Change 63.33% -29.3% 81.75%
Accrued Expenses $3.808M $5.046M $4.644M
YoY Change 5.16% 8.66% 25.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.144M $6.074M $6.098M
YoY Change 15.88% -0.39% 32.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.257M $1.256M $2.328M
YoY Change -24.96% -46.05% -3.0%
Total Long-Term Liabilities $1.257M $1.256M $2.328M
YoY Change -24.96% -46.05% -3.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.144M $6.074M $6.098M
Total Long-Term Liabilities $1.257M $1.256M $2.328M
Total Liabilities $8.714M $9.752M $10.64M
YoY Change 0.41% -8.3% 11.95%
SHAREHOLDERS EQUITY
Retained Earnings $132.3M $129.2M
YoY Change 10.89%
Common Stock $468.0K $358.0K
YoY Change 1200.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $121.8M $118.0M $109.2M
YoY Change
Total Liabilities & Shareholders Equity $130.5M $127.8M $119.8M
YoY Change 12.33% 6.65% 4.72%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $4.200M $4.214M $3.534M
YoY Change 2.36% 19.24% 16.87%
Depreciation, Depletion And Amortization $1.766M $155.0K $1.795M
YoY Change 0.11% -91.36% -1.37%
Cash From Operating Activities $4.913M $6.915M $5.046M
YoY Change 1.68% 37.04% -8.75%
INVESTING ACTIVITIES
Capital Expenditures $320.0K $43.00K -$237.0K
YoY Change -244.14% -118.14% 2270.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$320.0K -$43.00K -$237.0K
YoY Change 44.14% -81.86% 2270.0%
FINANCING ACTIVITIES
Cash Dividend Paid $1.070M $0.00
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.010M -$1.049M 19.00K
YoY Change -71.56% -5621.05% -102.0%
NET CHANGE
Cash From Operating Activities 4.913M $6.915M 5.046M
Cash From Investing Activities -320.0K -$43.00K -237.0K
Cash From Financing Activities -1.010M -$1.049M 19.00K
Net Change In Cash 3.583M $5.860M 4.828M
YoY Change 238.34% 21.38% 5.65%
FREE CASH FLOW
Cash From Operating Activities $4.913M $6.915M $5.046M
Capital Expenditures $320.0K $43.00K -$237.0K
Free Cash Flow $4.593M $6.872M $5.283M
YoY Change -9.12% 30.08% -4.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-12575
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
UTAH MEDICAL PRODUCTS INC
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0342734
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7043 South 300 West
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Midvale
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84047
CY2023Q1 dei City Area Code
CityAreaCode
801
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
566-1200
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, $0.01 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
UTMD
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3628067 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80912000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75052000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3818000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5538000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
9940000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8814000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
442000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
515000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
95112000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
89919000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10241000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10224000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
13502000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
13354000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
53443000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
52755000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
44528000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
42378000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
8915000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10377000 usd
CY2023Q1 us-gaap Assets
Assets
127770000 usd
CY2022Q4 us-gaap Assets
Assets
123874000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1028000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1218000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5046000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4742000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
6074000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5960000 usd
CY2023Q1 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1456000 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1514000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1256000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1256000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
328000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
341000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
638000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
549000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
9752000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
9620000 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3628000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3628000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3628000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3628000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-11490000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Before Tax1
AccumulatedOtherComprehensiveIncomeLossBeforeTax1
-12039000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
322000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
251000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
129150000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
126006000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
118018000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
114254000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
127770000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
123874000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12520000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12323000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4677000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4790000 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
7843000 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
7533000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3260000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2888000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
144000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
123000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
3404000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3011000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4439000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4522000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
680000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5119000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4530000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
905000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
996000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
4214000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
3534000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.16
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.97
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.16
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3628000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3655000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3636000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3665000 shares
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
549000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-506000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4763000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3028000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
4214000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
3534000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
155000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
149000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1596000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1646000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
13000 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
14000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-144000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
50000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
43000 usd
CY2023Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
2000 usd
CY2022Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1789000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
578000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1084000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
809000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-25000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
109000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-193000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
695000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
350000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
597000 usd
CY2023Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
2701000 usd
CY2022Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1512000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6915000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5046000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
237000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-43000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-237000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19000 usd
CY2023Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
1070000 usd
CY2022Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1049000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5860000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4899000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75052000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60974000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80912000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65873000 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
129000 usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
82000 usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2022Q1 us-gaap Interest Paid
InterestPaid
0 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
114254000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 usd
CY2023Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
50000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
549000 usd
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1070000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
4214000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
118018000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107138000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000 usd
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
43000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-506000 usd
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1060000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
3534000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
109168000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1935000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1896000 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1500000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1193000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
6505000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5725000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
9940000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
8814000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
50000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43000 usd
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3665000 shares
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12520000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
4214000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
3534000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3628000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3655000 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
8000 shares
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3636000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.16
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.97
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.16
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96

Files In Submission

Name View Source Status
0001811884-23-000013-index-headers.html Edgar Link pending
0001811884-23-000013-index.html Edgar Link pending
0001811884-23-000013.txt Edgar Link pending
0001811884-23-000013-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
utmd-20230331.htm Edgar Link pending
utmd-20230331.xsd Edgar Link pending
utmd_ex31z1.htm Edgar Link pending
utmd_ex31z2.htm Edgar Link pending
utmd_ex32z1.htm Edgar Link pending
utmd_ex32z2.htm Edgar Link pending
utmd-20230331_def.xml Edgar Link unprocessable
utmd-20230331_lab.xml Edgar Link unprocessable
utmd-20230331_pre.xml Edgar Link unprocessable
utmd-20230331_cal.xml Edgar Link unprocessable
utmd-20230331_htm.xml Edgar Link completed